Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [813]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [813]

Sedative use, genetics , 388

Selective mutism , 193–94

maintenance of gains , 215

treatment , 189 t, 194 , 214 t

Selective prevention programs , xxxv

anxiety disorders , 238–39

definition , xxxiv, 58

major depressive disorder , 64–66

suicide , 464–86

Selective serotonin and noradrenaline reuptake inhibitors, for major depressive disorder , 42

Selective serotonin reuptake inhibitors

for anxiety disorder, with substance use disorder , 409–10

for bulimia nervosa , 293

for generalized anxiety disorder , 195 , 197–98

for major depressive disorder

in adults , 42

in children and adolescents , 44 , 45–46 , 45 t

with substance use disorder , 409

for obsessive-compulsive disorder , 207–8

for panic disorder , 202 , 204

for phobia , 201–2

for post-traumatic stress disorder , 210 , 213

for separation anxiety disorder , 199

suicidal ideation and , xxxvi, 43–44 , 435 , 485 , 618

for suicide attempters , 483–84

Self-determination , 504

Self-efficacy , 504–5

Self-esteem/social competence (SESC) model, for prevention of eating disorders , 320–21

Self-harm, school professional findings , 601 , 602 t

Seligman, Martin , 506

Seligman program, for prevention of depression , 62–63 , 516 t

Sensitization

pharmacological , 337

to stimulants , 353

Sensory gating, in schizophrenia , 90 , 106

Separation, depression and , 13

Separation anxiety disorder

comorbidity , 169 , 169 t

description , 164

genetics , 180–81

signs and symptoms , 165 t

treatment , 189t–190 t, 198–99 , 214–15 , 214 t

Septal-hippocampal system, in anxiety disorders , 186–87

Serotonin

in alcohol use , 387

in anorexia nervosa , 292 , 311

in anxiety disorders , 187

in smoking , 386

in suicidal behavior , 439 , 482

Serotonin and noradrenaline reuptake inhibitors, selective, for major depressive disorder , 42

Serotonin reuptake inhibitors, selective . See Selective serotonin reuptake inhibitors

Serotonin transporter polymorphism

anxiety disorders and , 181

and depression after exposure to child abuse , xxxii, 14

Sertraline

for generalized anxiety disorder , 197–98

for major depressive disorder

in adults , 42

in children and adolescents , 44 , 45 t

for obsessive-compulsive disorder , 208

for panic disorder , 202

for post-traumatic stress disorder , 210

Service delivery systems

mental health

barriers , 550–55 , 571–72

organizational context findings , 557–60

recommendations , 560

reform initiatives , 555–57

settings , xxxvii–xxxviii

substance abuse , 572–76

emerging trends , 576–77

limited assessment practices , 572–74

limited scope and appropriateness , 574

step-down , 575

system change considerations , 575–76

Services for Teens at Risk (STAR) Center Outreach program , 465

Sex differences . See Gender differences

Sex hormones, and adolescent behavior , xxxi, 96

Sexual abuse

anorexia nervosa and , 310

post-traumatic stress disorder and , 211–12

suicidal behavior and , 440

victim identification, primary care physician findings , 584 , 584 t

Sexual assault, depression and , 14

Sexual behaviors, high-risk, alcohol-related , 359

Sexual orientation, suicidal behavior and , 438–39

Short stature, in anorexia nervosa , 277

Sibling influences, in alcohol use disorders , 361

Sibutramine, for bulimia nervosa , 294

Signal transduction, in drug addiction , 377–78

Signs of Suicide (SOS) Program , 446 , 448 t, 450

Skeletal abnormalities, in eating disorders , 276 t

Skills, Opportunities, and Recognition program , 516 t

Skin abnormalities, in eating disorders , 276 t

Slim body ideal

anorexia nervosa and , 309

bulimia nervosa and , 314

Smoking

and anxiety disorders , 228

end p.813